Acer Therapeutics (ACER) Plans Clinical Trial for EDSIVO Following Type B FDA Meeting

Go back to Acer Therapeutics (ACER) Plans Clinical Trial for EDSIVO Following Type B FDA Meeting
(NASDAQ: ACER) Delayed: 2.39 +0.05 (2.14%)
Previous Close $2.34    52 Week High
Open $2.39    52 Week Low
Day High $2.40    P/E N/A 
Day Low $2.33    EPS
Volume 81,197